Biosimilar Labeling Needs Greater Transparency, BIO And PhRMA Say
This article was originally published in The Pink Sheet Daily
Need for informed prescribing demands that products include the data that support biosimilarity, trade groups say in joint petition.
You may also be interested in...
Long-time CEO of the Biotechnology Innovation Organization will remain until after the 2020 election and help with the leadership transition.
The agency's website soon could include petitions' status in the process, potentially providing some solace to affected sponsors. FDA dockets management staff members are preparing to add live status updates and a listing of all pending citizen petitions to the website.
Agency website soon will include where petitions are in the process, potentially providing some solace to affected sponsors.